Groupe d'Etude en Oncologie du Quebec

Titre	Long Term Follow-Up of Patients Exposed to Lentiviral-Based CD19 Directed CAR T-Cell Therapy
Protocole ID	CCTL019A2205B
ClinicalTrials.gov ID	NCT02445222
Type(s) de cancer	Pédiatrique divers
Phase
Institution	CENTRE HOSPITALIER UNIVERSITAIRE SAINTE-JUSTINE
Ville	Montréal
Investigateur(trice) principal(e)	Dr Henrique Bittencourt
Coordonnateur(trice)	Maud Frizot 514-345-4931 poste 5467
Statut	Actif en recrutement
Critètes d'éligibilité	All patients who have received anti-CD19 directed CART therapy and completed or discontinued early from a Novartis sponsored treatment protocol that utilized CD19-directed CART cells or from any CD19 CART trial sponsored by the University of Pennsylvania with which Novartis has a contractual agreement to co-develop the CAR technology. Patients who have provided informed consent for the long term follow up study prior to their study participation .
Critètes d'exclusion	There are no specific exclusion criteria for this study.

Groupe d'étude en oncologie du Québec